OTC Products · LP-222
Loratadine Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-222OTC Products
- Generic identity
- LoratadineTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-222
- Generic ingredient
- Loratadine
- Dosage form
- Tablet
- Proposed strength
- 10 mg
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- OTC Products
About Loratadine
Loratadine is an H1 antihistamine used to relieve selected allergy symptoms. It is generally less sedating than many first-generation antihistamines, but some people still experience drowsiness. Its role is to control histamine-related symptoms rather than treat every nasal complaint or skin condition. The tablet presentation should be evaluated against the patient’s age, health and other medicines.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Allergic rhinitis and urticaria are common clinical contexts for antihistamine use. Review of triggers, symptom duration and response helps determine whether the diagnosis or management needs reconsideration. Loratadine does not replace emergency treatment of anaphylaxis. The single-ingredient tablet in this catalogue is different from products that combine loratadine with a decongestant, and their warnings or intended uses must not be merged.
Important safety considerations
Headache, tiredness and drowsiness can occur. Rare serious allergy requires urgent medical attention. Liver disease and interacting medicines can affect suitability and should be reviewed. People who experience sleepiness should avoid activities requiring alertness until assessed. Persistent symptoms, recurrent unexplained hives or breathing difficulty require appropriate medical review rather than unsupervised escalation or combining multiple antihistamines.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The entry lists a 10 mg tablet. Tablet scoring, rapidly dissolving properties, excipients and suitability for children or swallowing difficulties must be verified. Oral liquids and decongestant combinations are separate formulations.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the allergic diagnosis, age, liver history, interactions and impact on alertness. Review persistent symptoms and match the exact tablet to current local labeling.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Loratadine
- Dosage form / presentation
- Tablet
- Catalogue strength
- 10 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- OTC Products
Layer 02
Unresolved product-specific fields
- The catalogue establishes loratadine 10 mg tablets but does not state whether the tablet is conventional, chewable or orally disintegrating, whether it is scored, or the excipient composition.
- The blister count does not establish patient eligibility, dose schedule or interchangeability with liquid, chewable, capsule or rapidly disintegrating loratadine presentations.
- Approved indication, patient eligibility and dosing or test interpretation are not established by this portfolio record.
- Registration/authorization, manufacturing or site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Loratadinegovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength, excipients and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-222, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-222.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.